Primary Children's Hospital

About: Primary Children's Hospital is a healthcare organization based out in Salt Lake City, Utah, United States. It is known for research contribution in the topics: Population & Health care. The organization has 1770 authors who have published 2594 publications receiving 107857 citations. The organization is also known as: Intermountain Primary Children's Medical Center & Intermountain Primary Children's Hospital.

Self-termination from a child guidance center.

Abstract: Fifty-two household interviews were held with families who had self-terminated from a child guidance center. The purpose of these interviews was to determine reasons for self-termination and to measure the effectiveness of the center's program. Findings indicate that the most common reason for self-termination was (1) parents' expectations of therapy were not fulfilled, (2) general dissatisfaction with services, and (3) lack of progress. However, many of the self-terminators rated the center program highly and therefore it was concluded that many self-terminators do not actually reject psychotherapy. Inferences about the causes of self-termination and its alleviation are made.

Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Members of the Ceftibuten Pharyngitis International Study Group.

Abstract: The efficacy and safety of a 10-day course of ceftibuten oral suspension (9 mg/kg once daily) were compared with those of penicillin V (25 mg/kg/day in 3 divided doses) in children 3 to 18 years old treated for symptomatic pharyngitis and scarlet fever caused by group A beta-hemolytic streptococci (Streptococcus pyogenes). The study was prospective, randomized, multicenter and investigator-blinded ; patients were randomized in a 2 :1 ratio (ceftibuten :penicillin V). Overall clinical success (cure/improvement) at the primary end point of treatment (5 to 7 days posttherapy) was achieved in 97% (285 of 294) of ceftibuten-treated patients vs. 89% (117 of 132) of penicillin V-treated patients (P < 0.01). Elimination of infecting streptococci 5 to 7 days posttherapy was achieved in 91% (267 of 294) of ceftibuten-treated patients vs. 80% (105 of 132) of penicillin V-treated patients (P < 0.01). A significant rise in anti-streptolysin O or anti-DNase B was observed in approximately 30% of patients in both treatment groups. No patient developed rheumatic fever or nephritis. Treatment-related adverse events were similar between the two groups ; mild vomiting (2%) was most frequently reported. These data suggest that once daily ceftibuten is as safe as and more effective than three times daily penicillin V for the treatment of group A beta-hemolytic streptococcal pharyngitis.

Metformin treatment in young children with fragile X syndrome.

Abstract: Author(s): Biag, Hazel Maridith B; Potter, Laura A; Wilkins, Victoria; Afzal, Sumra; Rosvall, Alexis; Salcedo-Arellano, Maria Jimena; Rajaratnam, Akash; Manzano-Nunez, Ramiro; Schneider, Andrea; Tassone, Flora; Rivera, Susan M; Hagerman, Randi J | Abstract: BackgroundMetformin is a drug commonly used in individuals with type 2 diabetes, obesity, and impaired glucose tolerance. It has a strong safety profile in both children and adults. Studies utilizing the Drosophila model and knock out mouse model of fragile X syndrome (FXS) have found metformin to rescue memory, social novelty deficits, and neuroanatomical abnormalities. These studies provided preliminary evidence that metformin could be used as a targeted treatment for the cognitive and behavioral problems associated with FXS. Previously, a case series of children and adults with FXS treated with metformin demonstrated improvements in irritability, social responsiveness, language, and hyperactivity.MethodsHere, we present nine children with FXS between 2 and 7nyears of age who were treated clinically with metformin and monitored for behavioral and metabolic changes.ResultsParent reports and developmental testing before and after metformin are presented. There were improvements in language development and behavior (such as lethargy and stereotypy) in most of the patients.ConclusionThese results support the need for a controlled trial of metformin in children with FXS under 7nyears old whose brains are in a critical developmental window and thus may experience a greater degree of clinical benefit from metformin.